Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 64-68

  Zighelboim, Israel ^a   Wright, Jason D ^b   Gao, Feng ^c   Case, Ashley S ^d   Massad, L Stewart ^a   Mutch, David G ^a   Powell, Matthew A ^a   Thaker, Premal H ^a   Eisenhauer, Eric L ^e   Cohn, David E ^e   Valea, Fidel A ^f   Alvarez Secord, Angeles ^f   Lippmann, Lynne T ^a   Dehdashti, Farrokh ^g   Rader, Janet S ^h  

^a WASHINGTON UNIVERSITY   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c USA   (United States)

^d Hope A Women's Cancer Center   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f DUKE CANCER INSTITUTE   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bevacizumab PET CT; Cervical cancer; Chemotherapy; Cisplatin; Topotecan

Indexed keywords

BEVACIZUMAB; CISPLATIN; CREATININE; FLUORODEOXYGLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTOVAGINAL FISTULA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LEUKOPENIA; MULTIMODAL CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTOVAGINAL FISTULA; RECURRENT CANCER; SHOCK; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TOPOTECAN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84879111541     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.009     Document Type: Article

References (28)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global Cancer Statistics CA Cancer J Clin 61 2011 69 90
2. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2012 CA Cancer J Clin 62 2012 10 29
3. J.H. Hong, C.S. Tsai, C.H. Lai, T.C. Chang, C.C. Wang, and H.H. Chou Recurrent squamous cell carcinoma of cervix after definitive radiotherapy Int J Radiat Oncol Biol Phys 60 2004 249 257
4. T. Okawa, M. Kita, M. Goto, and E. Tazaki Radiation therapy alone in the treatment of carcinoma of the uterine cervix: review of experience at Tokyo Women's Medical College (1969-1983) Int J Radiat Oncol Biol Phys 13 1987 1845 1849
5. C.A. Perez, H.M. Camel, R.R. Kuske, M.S. Kao, A. Galakatos, and M.A. Hederman Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience Gynecol Oncol 23 1986 127 140
6. G.M. Sommers, P.W. Grigsby, C.A. Perez, H.M. Kamel, M.S. Kao, and A.E. Galakatos Outcome of recurrent cervical carcinoma following definitive irradiation Gynecol Oncol 35 1989 150 155
7. C.J. Wang, C.H. Lai, H.J. Huang, J.H. Hong, H.H. Chou, and K.G. Huang Recurrent cervical carcinoma after primary radical surgery Am J Obstet Gynecol 181 1999 518 524
8. P. Bonomi, J.A. Blessing, F.B. Stehman, P.J. DiSaia, L. Walton, and F.J. Major Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 3 1985 1079 1085
9. H.J. Long III, B.N. Bundy, E.C. Grendys Jr., J.A. Benda, D.S. McMeekin, J. Sorosky, and JV Fiorica Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 2005 4626 4633
10. B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4649 4655
11. M.S. Zaghloul, M. El Naggar, A. El Deeb, H. Khaled, and N. Mokhtar Prognostic implication of apoptosis and angiogenesis in cervical uteri cancer Int J Radiat Oncol Biol Phys 48 2000 1409 1415
12. S. Ozalp, O.T. Yalcin, U. Oner, H.M. Tanir, M. Acikalin, and I. Sarac Microvessel density as a prognostic factor in preinvasive and invasive cervical lesions Eur J Gynaecol Oncol 24 2003 425 428
13. J.S. Lee, H.S. Kim, J.T. Park, M.C. Lee, and C.S. Park Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status Anal Quant Cytol Histol 25 2003 303 311
14. I.J. Lee, K.R. Park, K.K. Lee, J.S. Song, K.G. Lee, and J.Y. Lee Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix Int J Radiat Oncol Biol Phys 54 2002 768 779
15. D.K. Gaffney, D. Haslam, A. Tsodikov, E. Hammond, J. Seaman, and J. Holden Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively effect overall survival in carcinoma of the cervix treated with radiotherapy Int J Radiat Oncol Biol Phys 56 2003 922 928
16. B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 27 2009 1069 1074
17. J.D. Wright, D. Viviano, M.A. Powell, R.K. Gibb, D.G. Mutch, and P.W. Grigsby Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer Gynecol Oncol 103 2006 489 493
18. E.A. Kidd, B.A. Siegel, F. Dehdashti, J.S. Rader, D.G. Mutch, and M.A. Powell Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis J Clin Oncol 28 2010 2108 2113
19. J.K. Schwarz, B.A. Siegel, F. Dehdashti, and P.W. Grigsby Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer Int J Radiat Oncol Biol Phys 83 2012 185 190
20. J. Trotman, M. Fournier, T. Lamy, J.F. Seymour, A. Sonet, and A. Janikova Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial patients J Clin Oncol 23 2011 3194 3200
21. L.K. Shankar, J.M. Hoffman, S. Bacharach, M.M. Graham, J. Karp, and A.A. Lammertsma Sullivan D; National Cancer Institute. Consensus recommendations for the use of 18 F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 2006 1059 1066
22. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-30
24. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 2004 3113 3119
25. K.K. Smith-McCune, and N. Weidner Demonstration and characterization of the angiogenic properties of cervical dysplasia Cancer Res 54 1994 800 804
26. N.M. Chau, P. Rogers, W. Aherne, V. Carroll, I. Collins, and E. McDonald Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors Cancer Res 65 2005 4918 4928
27. J. Dupuis, A. Berriolo-Riedinger, A. Julian, P. Brice, C. Tychyj-Pinel, and H. Tilly Impact of [18F]Fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS J Clin Oncol 30 2012 4317 4322
28. M. Kikuchi, Y. Nakamoto, S. Shinohara, K. Fujiwara, H. Yamazaki, and Y. Kanazawa Early evaluation of chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma Int J Clin Oncol 2012 [Epub ahead of print]